HK1220209A1 - 治疗急性肾损伤的方法 - Google Patents
治疗急性肾损伤的方法 Download PDFInfo
- Publication number
- HK1220209A1 HK1220209A1 HK16108216.3A HK16108216A HK1220209A1 HK 1220209 A1 HK1220209 A1 HK 1220209A1 HK 16108216 A HK16108216 A HK 16108216A HK 1220209 A1 HK1220209 A1 HK 1220209A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- kidney injury
- kidney
- treating acute
- acute kidney
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7019—Ischaemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7038—Hypoxia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775174P | 2013-03-08 | 2013-03-08 | |
| US61/775,174 | 2013-03-08 | ||
| PCT/US2014/022688 WO2014138738A1 (en) | 2013-03-08 | 2014-03-10 | Methods of treating acute kidney injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1220209A1 true HK1220209A1 (zh) | 2017-04-28 |
Family
ID=51492045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16108216.3A HK1220209A1 (zh) | 2013-03-08 | 2014-03-10 | 治疗急性肾损伤的方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160015701A1 (enExample) |
| EP (1) | EP2964671A4 (enExample) |
| JP (1) | JP2016512201A (enExample) |
| CN (1) | CN105324395A (enExample) |
| AU (1) | AU2014225320A1 (enExample) |
| BR (1) | BR112015020788A2 (enExample) |
| CA (1) | CA2901922A1 (enExample) |
| HK (1) | HK1220209A1 (enExample) |
| MX (1) | MX2015011730A (enExample) |
| WO (1) | WO2014138738A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014259961A1 (en) | 2013-04-30 | 2015-11-05 | Abbvie, Inc. | Methods for improving lipid profiles using atrasentan |
| WO2016073846A1 (en) * | 2014-11-07 | 2016-05-12 | Abbvie Inc. | Methods of treating ckd using predictors of fluid retention |
| EP3235496A1 (en) | 2016-04-19 | 2017-10-25 | Noorik Biopharmaceuticals AG | Treatment of acute renal failure |
| MA46459B1 (fr) * | 2016-10-05 | 2021-03-31 | Mitobridge Inc | Méthode de traitement de lésions rénales aiguës |
| KR102177349B1 (ko) * | 2018-02-13 | 2020-11-12 | 서울대학교병원 | 체세포 복제 효율 증진용 조성물 |
| US10978176B2 (en) | 2018-06-29 | 2021-04-13 | pulseData Inc. | Machine learning systems and methods for predicting risk of renal function decline |
| AU2020379649A1 (en) * | 2019-11-06 | 2022-05-26 | Mannin Research Inc. | Inhibition of the VE-PTP phosphatase protects the kidney from ischemia-reperfusion injury |
| US20220304979A1 (en) * | 2019-12-17 | 2022-09-29 | Chinook Therapeutics, Inc. | Methods of reducing disease flares |
| IL293921A (en) | 2019-12-17 | 2022-08-01 | Chinook Therapeutics Inc | Methods for treating iga kidney disease with atresantan |
| JP2023521169A (ja) * | 2020-04-10 | 2023-05-23 | チヌーク セラピューティクス,インコーポレイテッド | 糖尿病性腎疾患の処置方法 |
| CN113209111A (zh) * | 2021-05-14 | 2021-08-06 | 上海海糖生物医药科技有限公司 | 一种褐藻寡糖的应用 |
| CN115005157B (zh) * | 2022-06-02 | 2023-12-26 | 上海交通大学医学院附属新华医院 | 一种低氧致急性肾损伤动物模型的构建方法 |
| CN116731117B (zh) * | 2023-06-19 | 2024-05-10 | 武汉大学 | Kim-1靶向性多肽及其在急性肾损伤中肾靶向性的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273961A (en) * | 1992-09-22 | 1993-12-28 | Genentech, Inc. | Method of prophylaxis of acute renal failure |
| WO2005104702A2 (en) * | 2004-04-23 | 2005-11-10 | Renal Diagnostic, Inc. | An automated non- invasive real-time acute renal failure detection system |
| US20060205733A1 (en) * | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| US9255931B2 (en) * | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
-
2014
- 2014-03-10 HK HK16108216.3A patent/HK1220209A1/zh unknown
- 2014-03-10 BR BR112015020788A patent/BR112015020788A2/pt not_active IP Right Cessation
- 2014-03-10 WO PCT/US2014/022688 patent/WO2014138738A1/en not_active Ceased
- 2014-03-10 AU AU2014225320A patent/AU2014225320A1/en not_active Abandoned
- 2014-03-10 CN CN201480011012.2A patent/CN105324395A/zh active Pending
- 2014-03-10 US US14/772,621 patent/US20160015701A1/en not_active Abandoned
- 2014-03-10 EP EP14760019.1A patent/EP2964671A4/en not_active Withdrawn
- 2014-03-10 CA CA2901922A patent/CA2901922A1/en not_active Abandoned
- 2014-03-10 JP JP2015561753A patent/JP2016512201A/ja active Pending
- 2014-03-10 MX MX2015011730A patent/MX2015011730A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2964671A4 (en) | 2016-08-31 |
| CN105324395A (zh) | 2016-02-10 |
| EP2964671A1 (en) | 2016-01-13 |
| WO2014138738A1 (en) | 2014-09-12 |
| JP2016512201A (ja) | 2016-04-25 |
| MX2015011730A (es) | 2016-04-04 |
| BR112015020788A2 (pt) | 2017-10-10 |
| CA2901922A1 (en) | 2014-09-12 |
| WO2014138738A8 (en) | 2015-12-30 |
| US20160015701A1 (en) | 2016-01-21 |
| AU2014225320A1 (en) | 2015-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1220209A1 (zh) | 治疗急性肾损伤的方法 | |
| Martel-Pelletier et al. | Future therapeutics for osteoarthritis | |
| FIC20253001I1 (fi) | pharmaceutically acceptable salt thereof, particularly belzutifan | |
| NO2024001I1 (no) | Ritlecitinib, or a pharmaceutically acceptable salt thereof | |
| NO2022059I1 (no) | Lenacapavir or a pharmaceutically acceptable salt thereof, in particular lenacapavir sodium | |
| NO2025017I1 (no) | Acoramidis, and/or a pharmaceutically acceptable salt thereof, especially acoramidis hydrochloride | |
| FIC20253010I1 (fi) | Akalabrutinibi tai sen farmaseuttisesti hyväksyttävä suola, yhdessä venetoklaksin kanssa, valinnaisesti obinututsumabin kanssa tai ilman sitä | |
| LUC00083I2 (en) | Bictegravir or a pharmaceutically acceptable salt thereof, in particular bictegravir sodium | |
| HK1207000A1 (en) | Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies | |
| MX2021004308A (es) | Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria. | |
| BR112014029705A2 (pt) | composto ou sal, medicamento, métodos para inibir quinase de janus em um mamífero, e para a profilaxia ou tratamento de doenças autoimunes, e, uso de um composto ou sal | |
| Chung et al. | Multi-party international joint ventures: Multiple post-formation change processes | |
| CL2013003143A1 (es) | Uso de compuestos derivados de fenilaminopirimidinilo, un enantiomero o una sal farmaceuticamente aceptable del mismo para reducir la viabilidad de celulas de mieloma multiple en un estado de celulas no erspondedoras a il-6 y/o que tienen un fenotipo cd45-. | |
| BR112015007749A2 (pt) | métodos para tratamento de hipertensão , de hipercaliemia , e de doença renal crônica. | |
| HK1243430A1 (zh) | 通过施用il-6r拮抗剂治疗乾眼病的方法 | |
| EP3065712A4 (en) | Microparticles, methods for their preparation and use | |
| WO2015031598A3 (en) | Therapeutic dnp derivatives and methods using same | |
| SG11201506358PA (en) | Anti-cdh3 humanized antibody, drug conjugate thereof, and use thereof | |
| WO2014146111A3 (en) | Analgesic compounds and methods of use | |
| EP2959906A4 (en) | ADSORBENT FOR ORAL ADMINISTRATION, MEDICAMENT FOR RENAL DISEASE, AND MEDICAMENT FOR LIVER DISEASE | |
| EP2959905A4 (en) | ORAL ADMINISTRATIVE ADSORBENT, THERAPEUTIC AGENT AGAINST CHILDING DISEASE AND THERAPEUTIC AGENT AGAINST LIVER DISEASES | |
| EP2959908A4 (en) | ORAL ADMINISTRATIVE ADSORBENT, THERAPEUTIC AGENT AGAINST CHILDING DISEASE AND THERAPEUTIC AGENT AGAINST LIVER DISEASES | |
| EP2959907A4 (en) | ADSORBENT FOR ORAL ADMINISTRATION, MEDICAMENT FOR RENAL DISEASE, AND MEDICAMENT FOR LIVER DISEASE | |
| EP3064489A4 (en) | Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof | |
| Mwangi | Herbal medicines: do they really work |